Topiramate Explained

Verifiedfields:changed
Watchedfields:changed
Verifiedrevid:408971931
Width:175
Tradename:Topamax, Trokendi XR, Qudexy XR, others
Dailymedid:Topiramate
Pregnancy Au:D
Routes Of Administration:Oral
Atc Prefix:N03
Atc Suffix:AX11
Legal Au:S4
Legal Br:C1
Legal Br Comment:[1]
Legal Ca:Rx-only
Legal Uk:POM
Legal Us:Rx-only
Legal Us Comment:[2] [3] [4] [5] [6]
Legal Eu:Rx-only
Legal Eu Comment:[7]
Bioavailability:80%
Protein Bound:13–17%; 15–41%
Metabolism:Liver (20–30%)
Elimination Half-Life:21 hours
Excretion:Urine (70–80%)
Cas Number:97240-79-4
Pubchem:5284627
Iuphar Ligand:6849
Drugbank:DB00273
Chemspiderid:4447672
Unii:0H73WJJ391
Kegg:D00537
Chembl:220492
Pdb Ligand:TOR
Synonyms:Topiramic acid
Iupac Name:2,3:4,5-Bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamate
C:12
H:21
N:1
O:8
S:1
Smiles:O=S(=O)(OC[C@@]21OC(O[C@H]1[C@@H]3OC(O[C@@H]3CO2)(C)C)(C)C)N
Stdinchi:1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)/t7-,8-,9+,12+/m1/s1
Stdinchikey:KJADKKWYZYXHBB-XBWDGYHZSA-N

Topiramate, sold under the brand name Topamax among others, is a medication used to treat epilepsy and prevent migraines. It has also been used in alcohol dependence and essential tremor.[8] For epilepsy this includes treatment for generalized or focal seizures. It is taken orally (by mouth).[8]

Common side effects include tingling, feeling tired, loss of appetite, abdominal pain, weight loss,[9] and decreased cognitive function such as trouble concentrating.[8] [10] Serious side effects may include suicide, increased ammonia levels resulting in encephalopathy, and kidney stones.[8] Topiramate can cause birth defects including cleft lip and palate.[11] Risk/benefit should be carefully discussed with the full treatment team. Topiramate is considered "probably compatible" with lactation and is not contraindicated in breastfeeding, though monitoring of the infant for diarrhea or poor weight gain may be considered.[12] The mechanism of action is unclear.[8]

Topiramate was approved for medical use in the United States in 1996.[8] It is available as a generic medication.[10] [13] [14] In 2021, it was the 66th most commonly prescribed medication in the United States, with more than 10million prescriptions.[15] [16]

Medical uses

Topiramate is used to treat epilepsy in children and adults, and it was originally used as an anticonvulsant. In children, it is indicated for the treatment of Lennox-Gastaut syndrome, a disorder that causes seizures and developmental delay. It is most frequently prescribed for the prevention of migraines[17] as it decreases the frequency of attacks.[18] [19] Topiramate is used to treat medication overuse headache and is recommended by the European Federation of Neurological Societies as one of the few medications showing effectiveness for this indication.[20]

Pain

A 2018 review found topiramate of no use in chronic low back pain.[21] Topiramate has not been shown to work as a pain medicine in diabetic neuropathy, the only neuropathic condition in which it has been adequately tested.[22]

Other

One common off-label use for topiramate is in the treatment of bipolar disorder.[23] [24] [25] A review published in 2010 suggested a benefit of topiramate in the treatment of symptoms of borderline personality disorder, however the authors noted that this was based only on one randomized controlled trial and requires replication.[26]

Topiramate has been used as a treatment for alcoholism.[27] The U.S. Veterans Affairs and Department of Defense 2015 guidelines on substance use disorders list topiramate as a "strong for" in its recommendations for alcohol use disorder.[28]

Other uses include treatment of obesity,[29] [30] binge eating disorder,[31] and off-setting weight gain induced by taking antipsychotic medications.[32] [33] In 2012, the combination of phentermine/topiramate was approved in the United States for weight loss.

Adverse effects

People taking topiramate should be aware of the following risks:

Frequency

Adverse effects by incidence:[36] [37] [38] [39]

Very common (>10% incidence) adverse effects include:

Rarely, the inhibition of carbonic anhydrase may be strong enough to cause metabolic acidosis of clinical importance.[40]

The U.S. Food and Drug Administration (FDA) has notified prescribers that topiramate can cause acute myopia and secondary angle closure glaucoma in a small subset of people who take topiramate regularly.[41] The symptoms, which typically begin in the first month of use, include blurred vision and eye pain. Discontinuation of topiramate may halt the progression of the ocular damage and may reverse the visual impairment.

Preliminary data suggests that, as with several other anti-epileptic drugs, topiramate carries an increased risk of congenital malformations.[42] This might be particularly important for women who take topiramate to prevent migraine attacks. In March 2011, the FDA notified healthcare professionals and patients of an increased risk of development of cleft lip and/or cleft palate (oral clefts) in infants born to women treated with Topamax (topiramate) during pregnancy and placed it in Pregnancy Category D.[43]

Cognitive and word-finding difficulties, as they may occur in some patients, may respond to piracetam.[44] [45]

Carbonation dysgeusia (distortion of the sense of taste-sensation of carbonation) may respond to and/or be prevented to with zinc.[46]

Topiramate has been associated with a statistically significant increase in suicidality,[47] and "suicidal thoughts or actions" is now listed as one of the possible side effects of the drug "in a very small number of people, about 1 in 500."[48] [49]

Overdose

Symptoms of acute and acute on chronic exposure to topiramate range from asymptomatic to status epilepticus, including in patients with no seizure history.[50] [51] In children, overdose may also result in hallucinations.[51] Topiramate has been deemed the primary substance that led to fatal overdoses in cases that were complicated by polydrug exposure.[52] The most common signs of overdose are dilated pupils, somnolence, dizziness, psychomotor agitation, and abnormal, uncoordinated body movements.[50] [51] [52]

Interactions

Topiramate has many drug-drug interactions. Some of the most common are listed below:

Pharmacology

The topiramate molecule is a sulfamate modified sugar, more specifically, fructose diacetonide, an unusual chemical structure for a pharmaceutical.

Topiramate is quickly absorbed after oral use. It has a half life of 21 hours and a steady state of the drug is reached in 4 days in patients with normal renal function.[55] Most of the drug (70%) is excreted in the urine unchanged. The remainder is extensively metabolized by hydroxylation, hydrolysis, and glucuronidation. Six metabolites have been identified in humans, none of which constitutes more than 5% of an administered dose.

Several cellular targets have been proposed to be relevant to the therapeutic activity of topiramate.[56] These include (1) voltage-gated sodium channels; (2) high-voltage-activated calcium channels; (3) GABA-A receptors; (4) AMPA/kainate receptors; and (5) carbonic anhydrase isoenzymes. There is evidence that topiramate may alter the activity of its targets by modifying their phosphorylation state instead of by a direct action.[57] The effect on sodium channels could be of particular relevance for seizure protection. Although topiramate does inhibit high-voltage-activated calcium channels, the relevance to clinical activity is uncertain. Effects on specific GABA-A receptor isoforms could also contribute to the antiseizure activity of the drug. Topiramate selectively inhibits cytosolic (type II) and membrane associated (type IV) forms of carbonic anhydrase. The action on carbonic anhydrase isoenzymes may contribute to the drug's side-effects, including its propensity to cause metabolic acidosis and calcium phosphate kidney stones.

Topiramate inhibits maximal seizure activity in electroconvulsive therapy and in pentylenetetrazol-induced seizures as well as partial and secondarily generalized tonic-clonic seizures in the kindling model, findings predictive of a broad spectrum of activities clinically. Its action on mitochondrial permeability transition pores has been proposed as a mechanism.[58]

While many anticonvulsants have been associated with apoptosis in young animals, animal experiments have found that topiramate is one of the very few anticonvulsants [see: [[levetiracetam]], carbamazepine, lamotrigine] that do not induce apoptosis in young animals at doses needed to produce an anticonvulsant effect.[59]

Detection in body fluids

Blood, serum, or plasma topiramate concentrations may be measured using immunoassay or chromatographic methods to monitor therapy, confirm a diagnosis of poisoning in hospitalized patients, or to assist in a medicolegal death investigation. Plasma levels are usually less than 10 mg/L during therapeutic administration, but can range from 10 to 150 mg/L in overdose victims.[60] [61] [62]

History

Topiramate was discovered in 1979 by Bruce E. Maryanoff and Joseph F. Gardocki during their research work at McNeil Pharmaceuticals.[63] [64] Topiramate was first soldin 1996.[65] Mylan Pharmaceuticals was granted final approval by the FDA for the sale of generic topiramate in the United States and the generic version was made available in September 2006.[66] The last patent for topiramate in the U.S. was for use in children and expired on 28 February 2009.[67]

Research

Topiramate is being studied as a potential treatment for post traumatic stress disorder.[68]

There is some evidence for the use of topiramate in the management of cravings related to withdrawal from dextromethorphan.[69]

A 2023 systematic review of seizure treatment for infants aged 1 to 36 months identified three studies that evaluated the use of topiramate. Though its adverse effects including upper respiratory tract infection and loss of appetite were rarely severe enough for the medication to be discontinued in this age group, its effectiveness in reducing seizures was inconclusive. The available research suffers from small sample sizes, inconsistent findings, and inadequate comparison groups.[70]

Notes and References

  1. Web site: Anvisa . Brazilian Health Regulatory Agency . 31 March 2023 . RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial . Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control. live . https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 . 3 August 2023 . 16 August 2023 . . pt-BR . 4 April 2023.
  2. Web site: Trokendi XR- topiramate capsule, extended release . DailyMed . 8 November 2021 . 8 November 2021 . https://web.archive.org/web/20211108230847/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2dc7957e-a3e5-46bb-aa66-f3250f872f5e . live .
  3. Web site: Topamax- topiramate tablet, coated Topamax- topiramate capsule, coated pellets . DailyMed . 8 November 2021 . 8 November 2021 . https://web.archive.org/web/20211108230855/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=21628112-0c47-11df-95b3-498d55d89593 . live .
  4. Web site: Qsymia- phentermine and topiramate capsule, extended release . DailyMed . 8 November 2021 . 26 October 2021 . https://web.archive.org/web/20211026061736/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=40dd5602-53da-45ac-bb4b-15789aba40f9 . live .
  5. Web site: Qudexy XR- topiramate capsule, extended release . DailyMed . 8 November 2021 . 8 November 2021 . https://web.archive.org/web/20211108230852/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=46f54677-3a22-4c38-9b92-923020164e15 . live .
  6. Web site: Eprontia - topiramate solution . DailyMed . 19 December 2021 . 19 December 2021 . https://web.archive.org/web/20211219213622/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e2a4df59-fead-4a01-9021-9eda02c48010 . live .
  7. Web site: Active substance(s): topiramate . List of nationally authorised medicinal products . European Medicines Agency . September 2022 . 6 September 2022 . 6 September 2022 . https://web.archive.org/web/20220906054013/https://www.ema.europa.eu/en/documents/psusa/topiramate-list-nationally-authorised-medicinal-products-psusa/00002996/202201_en.pdf . live .
  8. Web site: Topiramate Monograph for Professionals . Drugs.com . American Society of Health-System Pharmacists . 5 March 2019 . 6 March 2019 . https://web.archive.org/web/20190306044425/https://www.drugs.com/monograph/topiramate.html . live .
  9. Web site: Topiramate Side Effects: Common, Severe, Long Term. 3 August 2021. Drugs.com. 10 April 2021. https://web.archive.org/web/20210410135224/https://www.drugs.com/sfx/topiramate-side-effects.html. live.
  10. Book: British national formulary : BNF 76. 2018. Pharmaceutical Press. 9780857113382. 328. 76.
  11. Web site: 18 June 2019 . FDA Drug Safety Communication: Risk of oral clefts in children born to mothers taking Topamax (topiramate) . FDA .
  12. Web site: Health . MGH Center for Women's Mental . 10 August 2022 . Essential Reads: Breastfeeding and Anti-Epileptic Drugs - MGH Center for Women's Mental Health . 27 December 2023 .
  13. Web site: Competitive Generic Therapy Approvals . U.S. Food and Drug Administration (FDA) . 29 June 2023 . 29 June 2023 . 29 June 2023 . https://web.archive.org/web/20230629233651/https://www.fda.gov/drugs/generic-drugs/competitive-generic-therapy-approvals . live .
  14. Web site: First Generic Drug Approvals 2023 . U.S. Food and Drug Administration (FDA) . 30 May 2023 . https://web.archive.org/web/20230630003621/https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/first-generic-drug-approvals . 30 June 2023 . live . 30 June 2023.
  15. Web site: The Top 300 of 2021 . ClinCalc . 14 January 2024 .
  16. Web site: Topiramate - Drug Usage Statistics . ClinCalc . 14 January 2024 .
  17. Web site: Topamax Prescribing Information. United States Food and Drug Administration. 11 April 2016. 24 April 2016. https://web.archive.org/web/20160424132704/http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020505s055,020844s046lbl.pdf. live.
  18. Linde M, Mulleners WM, Chronicle EP, McCrory DC . Topiramate for the prophylaxis of episodic migraine in adults . The Cochrane Database of Systematic Reviews . 6 . 6 . CD010610 . June 2013 . 23797676 . 7388931 . 10.1002/14651858.CD010610 .
  19. Ferrari A, Tiraferri I, Neri L, Sternieri E . Clinical pharmacology of topiramate in migraine prevention . Expert Opinion on Drug Metabolism & Toxicology . 7 . 9 . 1169–1181 . September 2011 . 21756204 . 10.1517/17425255.2011.602067 . 207491096 .
  20. Evers S, Jensen R . Treatment of medication overuse headache--guideline of the EFNS headache panel . European Journal of Neurology . 18 . 9 . 1115–1121 . September 2011 . 21834901 . 10.1111/j.1468-1331.2011.03497.x . 2698885 . free .
  21. Enke O, New HA, New CH, Mathieson S, McLachlan AJ, Latimer J, Maher CG, Lin CC . 6 . Anticonvulsants in the treatment of low back pain and lumbar radicular pain: a systematic review and meta-analysis . CMAJ . 190 . 26 . E786–E793 . July 2018 . 29970367 . 6028270 . 10.1503/cmaj.171333 .
  22. Wiffen PJ, Derry S, Lunn MP, Moore RA . Topiramate for neuropathic pain and fibromyalgia in adults . The Cochrane Database of Systematic Reviews . 8 . CD008314 . August 2013 . 2013 . 23996081 . 8406931 . 10.1002/14651858.CD008314.pub3 . 6 September 2013 . live . Derry S . https://web.archive.org/web/20140331085009/http://summaries.cochrane.org/CD008314/topiramate-for-treating-neuropathic-pain-or-fibromyalgia#sthash.QswJ7Tr9.dpuf . 31 March 2014 .
  23. Arnone D . Review of the use of Topiramate for treatment of psychiatric disorders . Annals of General Psychiatry . 4 . 1 . 5 . February 2005 . 15845141 . 1088011 . 10.1186/1744-859X-4-5 . free .
  24. Vasudev K, Macritchie K, Geddes J, Watson S, Young A . Topiramate for acute affective episodes in bipolar disorder . The Cochrane Database of Systematic Reviews . 1 . CD003384 . January 2006 . 16437453 . 10.1002/14651858.CD003384.pub2 . Young AH .
  25. Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, Purgato M, Spineli LM, Goodwin GM, Geddes JR . 6 . Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis . Lancet . 378 . 9799 . 1306–1315 . October 2011 . 21851976 . 10.1016/s0140-6736(11)60873-8 . 25512763 .
  26. Lieb K, Völlm B, Rücker G, Timmer A, Stoffers JM . Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials . The British Journal of Psychiatry . 196 . 1 . 4–12 . January 2010 . 20044651 . 10.1192/bjp.bp.108.062984 . free .
  27. Johnson BA, Ait-Daoud N . Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients . Current Pharmaceutical Design . 16 . 19 . 2103–2112 . 2010 . 20482511 . 3063512 . 10.2174/138161210791516404 .
  28. Web site: VA/DoD Clinical Practice Guideline for the management of substance use disorders. 31 December 2015. healthquality.va.gov. 30 August 2017. 31 August 2017. https://web.archive.org/web/20170831041618/https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPGRevised22216.pdf. live.
  29. Verrotti A, Scaparrotta A, Agostinelli S, Di Pillo S, Chiarelli F, Grosso S . Topiramate-induced weight loss: a review . Epilepsy Research . 95 . 3 . 189–199 . August 2011 . 21684121 . 10.1016/j.eplepsyres.2011.05.014 . 30103553 .
  30. Kramer CK, Leitão CB, Pinto LC, Canani LH, Azevedo MJ, Gross JL . Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials . Obesity Reviews . 12 . 5 . e338–e347 . May 2011 . 21438989 . 10.1111/j.1467-789X.2010.00846.x . 24358798 . free .
  31. Web site: Topiramate for Binge Eating Disorder. 3 August 2021. wa.kaiserpermanente.org. 3 August 2021. https://web.archive.org/web/20210803095925/https://wa.kaiserpermanente.org/kbase/topic.jhtml?docId=ty7109. live.
  32. Hahn MK, Cohn T, Teo C, Remington G . Topiramate in schizophrenia: a review of effects on psychopathology and metabolic parameters . Clinical Schizophrenia & Related Psychoses . 6 . 4 . 186–196 . January 2013 . 23302448 . 10.3371/CSRP.HACO.01062013 .
  33. Mahmood S, Booker I, Huang J, Coleman CI . Effect of topiramate on weight gain in patients receiving atypical antipsychotic agents . Journal of Clinical Psychopharmacology . 33 . 1 . 90–94 . February 2013 . 23277264 . 10.1097/JCP.0b013e31827cb2b7 . 26085987 .
  34. Web site: Topamax (topiramate) tablets and sprinkle capsules. Fda.gov. 17 October 2014. 12 January 2017. https://web.archive.org/web/20170112172852/http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm195797.htm. live.
  35. Web site: 8 August 2021 . Seizures and Epilepsy in Children . 19 July 2023 . www.hopkinsmedicine.org .
  36. Web site: Topamax Tablets and Sprinkle Capsules PRODUCT INFORMATION. TGA eBusiness Services. JANSSEN-CILAG Pty Ltd. 30 May 2013. 18 November 2013. PDF. 29 March 2019. https://web.archive.org/web/20190329054936/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2012-PI-02205-3. live.
  37. Web site: topiramate (Rx) - Topamax, Trokendi XR. Medscape Reference. WebMD. 18 November 2013. 19 May 2019. https://web.archive.org/web/20190519021543/https://reference.medscape.com/drug/topamax-trokendi-xr-topiramate-343023. live.
  38. Web site: Topiramate 100 mg film-coated Tablets. electronic Medicines Compendium. Sandoz Limited. 6 March 2013. 18 November 2013. https://web.archive.org/web/20140521031853/http://www.medicines.org.uk/emc/medicine/22416/SPC/Topiramate+100+mg+film-coated+Tablets/ . 21 May 2014 . dead.
  39. Web site: TOPIRAMATE (topiramate) tablet TOPIRAMATE (topiramate) tablet [Torrent Pharmaceuticals Limited]]. DailyMed. Torrent Pharmaceuticals Limited. August 2011. 18 November 2013. 20 May 2014. https://web.archive.org/web/20140520220544/http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a4ff77b8-04bc-4edb-a085-8d6d8687f8d1. live.
  40. Mirza N, Marson AG, Pirmohamed M . Effect of topiramate on acid-base balance: extent, mechanism and effects . British Journal of Clinical Pharmacology . 68 . 5 . 655–661 . November 2009 . 19916989 . 2791971 . 10.1111/j.1365-2125.2009.03521.x .
  41. Web site: IMPORTANT DRUG WARNING. Hulihan J . 2001. FDA MedWatch. Ortho-McNeil Pharmaceutical. https://wayback.archive-it.org/7993/20170113165159/https://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM173936.pdf. 13 January 2017. dead. 11 June 2018.
  42. Hunt S, Russell A, Smithson WH, Parsons L, Robertson I, Waddell R, Irwin B, Morrison PJ, Morrow J, Craig J . 6 . Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register . Neurology . 71 . 4 . 272–276 . July 2008 . 18645165 . 10.1212/01.wnl.0000318293.28278.33 . 13562052 .
  43. Web site: Risk of oral clefts in children born to mothers taking Topamax (topiramate) . FDA Drug Safety Communication . Fda.gov . 6 January 2011 . 11 July 2013 . 24 April 2019 . https://web.archive.org/web/20190424012653/https://www.fda.gov/Drugs/DrugSafety/ucm245085.htm . live .
  44. Berthier, M.L. and Dávila, G., 2023. Pharmacotherapy for post-stroke aphasia: what are the options?. Expert Opinion on Pharmacotherapy, (just-accepted).
  45. Cumbo, E. and Ligori, L.D., 2010. Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer’s disease. Epilepsy & Behavior, 17(4), pp.461-466.
  46. Charbonneau, M., Doyle-Campbell, C., Laskey, C. and Capoccia, K., 2020. Carbonation dysgeusia associated with topiramate. American Journal of Health-System Pharmacy, 77(14), pp.1113-1116.
  47. Web site: Suicidality and Antiepileptic Drugs . . 11 July 2013 . 10 May 2017 . https://web.archive.org/web/20170510065536/https://www.fda.gov/ohrms/dockets/ac/08/slides/2008-4344s1_09_01_Trileptal . live .
  48. Web site: Possible Side Effects - Topamax (topiramate). https://web.archive.org/web/20110128083201/http://www.topamax.com/how-topamax-may-help--what-to-expect.html. dead. 28 January 2011. Topamax.xom. 17 October 2014.
  49. Web site: Topiramate . https://web.archive.org/web/20100805062310/http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000998/ . 5 August 2010 . PubMed Health . National Center for Biotechnology Information, U.S. National Library of Medicine .
  50. Wiśniewski M, Łukasik-Głebocka M, Anand JS . Acute topiramate overdose--clinical manifestations . Clinical Toxicology . 47 . 4 . 317–320 . April 2009 . 19514879 . 10.1080/15563650601117954 . 205901501 .
  51. Wills B, Reynolds P, Chu E, Murphy C, Cumpston K, Stromberg P, Rose R . Clinical outcomes in newer anticonvulsant overdose: a poison center observational study . Journal of Medical Toxicology . 10 . 3 . 254–260 . September 2014 . 24515527 . 4141920 . 10.1007/s13181-014-0384-5 .
  52. Lofton AL, Klein-Schwartz W . Evaluation of toxicity of topiramate exposures reported to poison centers . Human & Experimental Toxicology . 24 . 11 . 591–595 . November 2005 . 16323576 . 10.1191/0960327105ht561oa . 2005HETox..24..591L . 37784043 .
  53. Book: Sweetman SC . Sex hormones and their modulators. Martindale: The complete drug reference . 36th . 2009 . 2068 . Pharmaceutical Press . London. 978-0-85369-840-1. Martindale: The complete drug reference.
  54. Web site: TOPAMAX (topiramate) Tablets Approved Labeling Text . 29 June 2005 . Ortho-McNeil Pharmaceutical . U.S. Food and Drug Administration . https://web.archive.org/web/20070205092259/https://www.fda.gov/cder/foi/label/2005/020505s018lbl.pdf . 5 February 2007 . 14.
  55. Web site: FDA Data on Topamax. live. 6 August 2021. 6 August 2021. https://web.archive.org/web/20210806051822/https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020505s038s039,020844s032s034lbl.pdf.
  56. Book: Porter RJ, Dhir A, Macdonald RL, Rogawski MA . Mechanisms of action of antiseizure drugs . Handb Clin Neurol . 2012 . 108 . 663–681 . 10.1016/B978-0-444-52899-5.00021-6 . 22939059 . http://works.bepress.com/michael_rogawski/41/ . Handbook of Clinical Neurology . 9780444528995 . 22 May 2014 . 22 June 2017 . https://web.archive.org/web/20170622140812/https://works.bepress.com/michael_rogawski/41/ . dead .
  57. Meldrum BS, Rogawski MA . Molecular targets for antiepileptic drug development . Neurotherapeutics . 4 . 1 . 18–61 . January 2007 . 17199015 . 1852436 . 10.1016/j.nurt.2006.11.010 .
  58. Kudin AP, Debska-Vielhaber G, Vielhaber S, Elger CE, Kunz WS . The mechanism of neuroprotection by topiramate in an animal model of epilepsy . Epilepsia . 45 . 12 . 1478–1487 . December 2004 . 15571505 . 10.1111/j.0013-9580.2004.13504.x . 7067509 . free .
  59. Czuczwar K, Czuczwar M, Cieszczyk J, Gawlik P, Luszczki JJ, Borowicz KK, Czuczwar SJ . [Neuroprotective activity of antiepileptic drugs] . Przeglad Lekarski . 61 . 11 . 1268–1271 . 2004 . 15727029 .
  60. Goswami D, Kumar A, Khuroo AH, Monif T, Rab S . Bioanalytical LC-MS/MS method validation for plasma determination of topiramate in healthy Indian volunteers . Biomedical Chromatography. 23 . 11 . 1227–41 . November 2009 . 19593736 . 10.1002/bmc.1273 .
  61. Brandt C, Elsner H, Füratsch N, Hoppe M, Nieder E, Rambeck B, Ebner A, May TW . 6 . Topiramate overdose: a case report of a patient with extremely high topiramate serum concentrations and nonconvulsive status epilepticus . Epilepsia . 51 . 6 . 1090–1093 . June 2010 . 19889015 . 10.1111/j.1528-1167.2009.02395.x . 35752877 .
  62. Book: Baselt R . Disposition of Toxic Drugs and Chemicals in Man . 8th . Biomedical Publications . Foster City, CA . 2008 . 1567–1569 .
  63. Maryanoff BE, Nortey SO, Gardocki JF, Shank RP, Dodgson SP . Anticonvulsant O-alkyl sulfamates. 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate and related compounds . Journal of Medicinal Chemistry . 30 . 5 . 880–887 . May 1987 . 3572976 . 10.1021/jm00388a023 .
  64. Maryanoff BE, Costanzo MJ, Nortey SO, Greco MN, Shank RP, Schupsky JJ, Ortegon MP, Vaught JL . 6 . Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives . Journal of Medicinal Chemistry . 41 . 8 . 1315–1343 . April 1998 . 9548821 . 10.1021/jm970790w .
  65. Book: Pitkänen A, Schwartzkroin PA, Moshé SL . Models of Seizures and Epilepsy . 2005 . Elsevier . Burlington . 9780080457024 . 539 . 17 September 2017. 8 September 2017. https://web.archive.org/web/20170908192246/https://books.google.com/books?id=Qw6KqLjwtZQC&pg=PA539. live.
  66. Web site: Waknine Y . 22 September 2006 . First-Time Generic Approvals: Seasonale, Imodium Advanced, and Topamax . Medscape.com . 11 July 2013 . 20 May 2013 . https://web.archive.org/web/20130520134911/http://www.medscape.com/viewarticle/544994 . live .
  67. Web site: Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Accessdata.fda.gov. 17 October 2014. 25 April 2016. https://web.archive.org/web/20160425045412/http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_No=020844&Product_No=002&table1=OB_Rx. live.
  68. Andrus MR, Gilbert E . Treatment of civilian and combat-related posttraumatic stress disorder with topiramate . The Annals of Pharmacotherapy . 44 . 11 . 1810–1816 . November 2010 . 20923947 . 10.1345/aph.1P163 . 12137726 .
  69. Roy AK 3rd, Hsieh C, Crapanzano K. Dextromethorphan Addiction Mediated Through the NMDA System: Common Pathways With Alcohol? J Addict Med. 2015 Nov-Dec;9(6):499-501. doi: 10.1097/ADM.0000000000000152. PMID 26441400.
  70. Treadwell JR, Wu M, Tsou AY . 25 October 2022 . Management of Infantile Epilepsies . 10.23970/ahrqepccer252 . doi . Agency for Healthcare Research and Quality .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Topiramate".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.